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Background: Tumor heterogeneity and the plasticity of cancer cells present challenges for effective clinical
diagnosis and therapy. Such challenges are epitomized by neuroendocrine transdifferentiation (NED) and the
emergence of neuroendocrine-like cancer cells in prostate tumors. This phenomenon frequently arises from
androgen-depleted prostate adenocarcinoma and is associated with the development of castration-resistant
prostate cancer and poor prognosis.
Results: In this study, we showed that NED was evoked in both androgen receptor (AR)-positive and AR-negative
prostate epithelial cell lines by growing the cells to a high density. Androgen depletion and high-density cultivation
were both associated with cell cycle arrest and deregulated expression of several cell cycle regulators, such as
p27Kip1, members of the cyclin D protein family, and Cdk2. Dual inhibition of Cdk1 and Cdk2 using pharmacological
inhibitor or RNAi led to modulation of the cell cycle and promotion of NED. We further demonstrated that the cyclic
adenosine 3′, 5′-monophosphate (cAMP)-mediated pathway is activated in the high-density conditions. Importantly,
inhibition of cAMP signaling using a specific inhibitor of adenylate cyclase, MDL-12330A, abolished the promotion of
NED by high cell density.
Conclusions: Taken together, our results imply a new relationship between cell cycle attenuation and promotion
of NED and suggest high cell density as a trigger for cAMP signaling that can mediate reversible NED in prostate
cancer cells.
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signalingBackground
Prostate cancer is one of the leading causes of cancer in
men worldwide. Although the growth of both normal
prostate epithelial cells and cancer cells is dependent on
the presence of androgens, chemical or surgical androgen
depletion therapy is the mainstay of treatment for meta-
static prostate disease. However, in many patients an
androgen-independent (castration-resistant) form of pros-
tate cancer develops within 18–24 months. Castration-* Correspondence: ksoucek@ibp.cz
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unless otherwise stated.resistant prostate cancer (CRPC) is currently an incurable
stage with poor prognosis [1]. During attempts to find
new treatment modalities for CRPC it has been hypothe-
sized that one of the events contributing to the develop-
ment of anti-androgen resistance is neuroendocrine
transdifferentiation (NED) of prostate cancer cells (sum-
marized in [2]). NED thus serves as an example of one of
the many levels of tumor heterogeneity and cancer cell
plasticity that in general represent a challenging issue for
effective clinical diagnosis and therapy [3].
In prostate carcinoma there is an increase in the number
of cells with neuroendocrine-like properties over time.
Because normal NE cells are thought to be post-mitotic
[4], it is proposed that new cells with NE-like propertiesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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epithelial cancer cells [5]. Such cancer cells acquire a NE-
like phenotype—they are able to secrete several neuropep-
tides and are androgen-independent. It was shown that
NED can be induced in vitro by various stimuli, such as
androgen depletion [6,7], increased levels of interleukin-6
(IL-6) [8], activation of Wnt [9] and EGF [10] signaling
pathways, activation of the cyclic adenosine 3′, 5′-mono-
phosphate (cAMP) signaling pathway [11-13], or ionizing
radiation [14,15]. In addition, several genes and transcrip-
tion factors were shown to be involved in NED, for ex-
ample protocadherin-PC and the transcription factors
Foxa2 and NeuroD1 (summarized in [2]).
Androgen depletion, which induces NED, is associated
with cell cycle arrest in G1 phase [16,17]. This cell cycle
arrest is linked to modulation of well-known cell cycle
regulators involved in G1 phase progression and the G1 to
S phase transition [16,18]. Another mechanism that con-
tributes to cell cycle arrest is the phenomenon of contact
inhibition. High-density cultivation is associated with
arrest in G1 phase that is accompanied by decreased Cdk2
and Cdk4 activity, even in cancer cells that are refractory
to the typical contact inhibition exhibited by normal cells.
Furthermore, cell density can also influence intracellular
signaling, as shown by density-dependent changes in
intra- and extra-cellular distribution of cAMP [19].
In the present study, we focused on the role of cell cycle
modulation in the regulation of NED in prostate cancer
cells. We showed that androgen depletion and cell cycle
modulation mediated by high cell density both promoted
NED, which was demonstrated by increased expression of
characteristic markers both in AR-positive and AR-
negative prostate epithelial cell lines of different origin.
We identified an important role of Cdk1 and Cdk2 activity
in promoting NED by cell cycle attenuation. Finally, our
results suggest a role of cAMP signaling activation in
NED promotion by high cell density in AR-positive pros-
tate cancer cell lines. Taken together, our data identify a
novel condition leading to the promotion of NED in pros-
tate cancer cells and define specific molecular mecha-
nisms that determine this process.
Results
Androgen depletion and high cell density promote NED
characteristics of prostate cancer cells
NED markers have diverse biologic functions: γ-enolase is
one of the iso-enzymes of the glycolytic enzyme enolase,
which catalyzes the conversion of 2-phospho-glycerate to
phosphoenolpyruvate and is found in mature neurons
(summarized in [20]); cytoskeletal protein tubulin β-III is
an early marker of neuronal differentiation [21]; chromo-
granin A is a prohormone expressed in endocrine cells
and peptidergic neurons that mediates granule formation
(summarized in [22]); and L-dopa decarboxylase is anenzyme involved in the synthesis of dopamine, serotonin,
and tryptamine that was shown to interact with androgen
receptor (AR) [23]. We decided to assess several different
markers of NED at both the protein and mRNA level be-
cause the expression of different NED markers may not
correlate in every experimental set-up, as was shown for
γ-enolase and chromogranin A in LNCaP cells undergoing
NED [24].
Androgen depletion in LNCaP cells increased protein
levels of the widely used NED markers γ-enolase, tubulin
β-III [25] (Figure 1A, right panel) and mRNA levels of the
NED markers γ-enolase (ENO2) and aromatic L-amino-
acid decarboxylase (DDC) [26] (Figure 1B). Surprisingly,
NED markers were also up-regulated at both protein and
mRNA levels in cells cultivated at high density in the pres-
ence of androgens (FBS, day 8 and 16). Importantly, simi-
lar effects of androgen depletion and high density in
promoting NED were observed in another prostate cancer
cell line, LAPC-4 (Figure 1A, B). Immunofluorescence
analysis of tubulin β-III expression showed a positive
signal in LNCaP cells cultivated for 16 days under
androgen-depleted conditions in dextran/charcoal-stripped
serum-containing medium (16d CS) or under high cell
density conditions after cultivation for 16 days in FBS (16d
FBS), where the signals were detected mainly on the edges
of high-density areas (Figure 1C).
Contradictory results have been published regarding the
reversibility of NED in prostate cancer cells [6,27]. There-
fore, we investigated whether NED promoted by androgen
depletion or high cell density is a reversible or irreversible
process. The expression of γ-enolase decreased in both
cell lines when cells cultivated for 16 days in the presence
of FBS were re-seeded into FBS at low density and culti-
vated for another 4 to 8 days (Additional file 1: Figure
S1A). However, splitting CS-cultivated cells (after 16 days)
from CS to either FBS or CS at low density did not
decrease the androgen depletion-enhanced protein level
of γ-enolase during further cultivation for up to 8 days
after re-seeding. This may imply that the NED phenotype
is reversible when evoked by high cell density (FBS), but
irreversible when promoted by androgen depletion (CS).
High cell density promotes NED in both AR-positive and
AR-negative prostate epithelial cell lines
The regulation of NED by high cell density in both LNCaP
(androgen-sensitive) and LAPC-4 (androgen-dependent)
cells led us to propose the hypothesis that cultivation at a
high cell density may modulate the expression and activity
of AR. In LNCaP cells, high cell density did not affect the
protein level of AR (Figure 1D, left panel). Androgen
depletion initially induced a decrease in the protein level
of AR but after 16 days of cultivation AR expression
returned to a level comparable to that of the control. In
contrast, AR expression was decreased in LAPC-4 cells in
Figure 1 Androgen depletion and high cell density both promote neuroendocrine transdifferentiation (NED) of LNCaP and LAPC-4 cells
independent of AR activity. LNCaP and LAPC-4 cells were cultivated for 2 to 16 days in the presence (FBS) or absence (CS) of androgens in the
cultivation medium. A, Western blot analysis of the expression of γ-enolase and tubulin β-III. B, qRT-PCR analysis of changes in mRNA levels of L-dopa
decarboxylase (DDC), chromogranin A (CHGA), and γ-enolase (ENO2). The bars represent means ± standard deviation (SD) from three independent
experiments. C, Immunofluorescence detection of tubulin β-III expression in LNCaP cells. D, Western blot analysis of changes in expression of androgen
receptor (AR) in LNCaP and LAPC-4 cells. AR activity was assessed by (E) western blot analysis of protein levels of androgens-regulated protein tumor
necrosis factor receptor superfamily member 10D (DcR2), and (F) qRT-PCR analysis of changes in mRNA levels of the prostate-specific antigen (KLK3).
The data represent means ± SD of three independent experiments. “*”denotes statistical significance (P < 0.05) compared with control (2 days in FBS).
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(Figure 1D, right panel). Next, we analyzed changes in ex-
pression levels of downstream targets of AR, namely the
tumor necrosis factor receptor superfamily member 10D
(decoy receptor 2, DcR2), expression of which is regulated
by androgens [28,29], and prostate-specific antigen (PSA,
encoded by the KLK3 gene). In both cell lines tested, high
cell density cultivation (FBS) was associated with an
increase in DcR2 protein expression and up-regulation of
KLK3 mRNA level (Figures 1E and F, respectively) imply-
ing increasing activity of AR in this model. As expected,
expression of both androgen-regulated genes was inhib-
ited when cells were cultivated in the absence of andro-
gens (CS), which is indicative of decreasing AR activity.
Taken together, these results showed that high cell
density-induced NED promotion in AR-positive prostate
cancer cell lines LNCaP and LAPC-4 in comparison to
CS-induced NED is not associated with the inhibition of
AR activity.
To further strengthen our results obtained from AR-
expressing prostate cancer cell lines, we performed high-
density cultivation experiments with the AR-negative
prostate cancer cell lines PC3 and DU-145 (Additional
file 1: Figure S1B-D). Cultivation of PC3 and DU-145 at
high density for 10 days led to up-regulation of the NED
marker γ-enolase at both the protein and mRNA level
(Additional file 1: Figure S1B, D). Moreover, we observed
a similar increase in γ-enolase protein in PC3 cells stably
transfected with AR [30] (Additional file 1: Figure S1C)
when cultivated at high density (Additional file 1: Figure
S1B). Concurrently, the mRNA for AR-regulated gene for
DcR2 (TNFRSF10D) was increased in response to high cell
density cultivation (Additional file 1: Figure S1E). These
results support our hypothesis that the promotion of NED
in response to high density may occur in both AR-positive
and AR-negative prostate epithelial cell lines.
The effect of high density on NED promotion was also
assessed during growth under three-dimensional (3D)
conditions using an Alvetex® scaffold (Additional file 2:
Figure S2A). Western blot analysis showed that expres-
sion of NED markers tubulin β-III and γ-enolase in
LNCaP and LAPC-4 cells increased at both the protein
and mRNA level with increasing seeding density in 3D
conditions (Figure 2A). Confocal microscopy confirmed
that cells cultivated in a 3D scaffold expressed the NED
marker tubulin β-III (Additional file 3: Figure S2B).
Changes in AR activity, assessed by expression of its down-
stream targets DcR2 (TNFRSF10D gene) and PSA (KLK3
gene) at the protein and/or mRNA level (Figure 2A), were
similar to those of high density-promoted NED in 2D
conditions (Figure 1E, F). Moreover, similar results were
obtained for C4-2 cells, an androgen-independent subline
of LNCaP, in both the presence (FBS) and absence (CS) of
androgens (Figure 2B).Again, we observed that high density in 3D conditions
evoked NED in both AR-positive and AR-negative cell
lines, as in 2D conditions (Figure 1 and Additional file 1:
Figure S1B-D), because cultivation in 3D at high density
also increased the expression of NED markers at both
protein and mRNA level in the AR-negative prostate cell
line BPH-1 and its tumorigenic clone CAFTD03, as well
as in the prostate cancer cell lines PC3 and DU-145
(Figure 2C). Similar to results obtained for 2D culture,
γ-enolase was up-regulated in PC3 cells stably express-
ing AR in 3D conditions. Moreover, when comparing
different seeding densities on Alvetex scaffold, mRNA
level for DcR2 gene TNFRSF10D increased in 3D condi-
tions in PC3-AR cell line (Additional file 1: Figure S2C).
To confirm the uniformity of AR activity in response
to high cell density at a single cell level, we used the
Stellaris® RNA FISH technique to assess KLK3 mRNA
expression in situ. As shown in Additional file 3: Figure
S3A, the higher frequency of KLK3 transcript per cell
was detected in high-density cultivation (12 days FBS) in
compare with low density cultivation (2 days FBS) espe-
cially in LNCaP cells. Heterogeneity of AR activity in
LAPC-4 cells in low high cell density condition is compar-
able. On the other hand, the signal was totally absent after
cultivation in androgen-depleted conditions (12 days CS).
These trends correlate with the KLK3 qRT-PCR analysis
(Figure 1F). Next, we detected prostate specific membrane
antigen (PSMA) using flow cytometry (Additional file 3:
Figure S3B). Consistent with published data showing that
PSMA is repressed by androgens [31], we detected
decreased expression of PSMA in both LNCaP and LAPC-
4 cells after 8 days of cultivation at high density in complete
medium (8 days FBS) compared with androgen-depleted
cultivation (8 days CS). We did not detect any subpopula-
tions or significant differences in the heterogeneity of
PSMA expression using flow cytometry. We can conclude
that the activity of AR in high-density conditions is higher
or comparable with low density condition and significantly
higher in compare with androgen-depleted cultivation.
In summary, these results show that high density and
androgen depletion both increase the expression of
NED markers in prostate cancer cell lines. Interestingly
our data demonstrated capability of high cell density to
promote NED in both AR-positive and AR-negative cell
lines in both 2D and 3D condition. Moreover NED pro-
motion in the high cell density condition was paralleled
with increased activity of AR in AR-positive cell lines.
Promotion of NED in response to high cell density or
androgen depletion is accompanied by cell cycle arrest
Long-term androgen depletion led to arrest of LNCaP and
LAPC-4 cells in the G0/G1 phase of the cell cycle
(Figure 3A). Although induction of cell cycle arrest by
high cell density was slower than that induced by
Figure 2 High cell density promotes NED of prostate cell lines cultured in 3D conditions independent of AR status. A, Analysis of NED
marker expression in LNCaP and LAPC-4 cells seeded on Alvetex® scaffold at increasing density (0.5 × 106, 1.0 × 106, and 1.5 × 106). Western blot
(upper) and qRT-PCR (lower) analysis of the NED markers γ-enolase (ENO2) and tubulin β-III (TUBB3). Activity of AR was examined by detection of
expression of the androgen-regulated protein DcR2 at protein and mRNA level (TNFRSF10D) and PSA at mRNA level (KLK3) in 3D conditions.
B, Western blot (upper) and qRT-PCR (lower) analysis of NED markers in the C4-2 cell line (LNCaP androgen-independent clone) in 3D conditions.
Activity of AR was confirmed by detection of DcR2 at both protein and mRNA level (TNFRSF10D) and PSA at mRNA level (KLK3). C, Changes in protein
(upper) and mRNA (lower) levels of NED markers after 3D cultivation of AR-negative prostate cell lines BPH-1, CAFTD03, PC3, DU-145, and PC3 cells
stably transfected with AR (PC3-AR). qRT-PCR data are presented as mean ± S.D. of two independent experiments except for results for C4-2, which are
from one experiment. Triangle represents increasing seeding density in 3D conditions on Alvetex (0.5 × 106, 1.0 × 106, and 1.5 × 106, respectively).
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Figure 3 Androgen depletion and high cell density both induce cell cycle arrest in LNCaP and LAPC-4 cells. A, Analysis of changes in cell
cycle distribution in response to high cell density (FBS) and androgen depletion (CS). The data represent means ± SD of three independent
experiments. “*”denotes statistical significance compared with control (2 days in FBS), “#” denotes statistical significance compared with 2 days in
CS. B, Western blot analysis of the expression of selected cell cycle regulators in LNCaP and LAPC-4 cells. Graphs represent optical density (O.D.)
of p-Cdk2 normalized to O.D. of total Cdk2.
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G0/G1 phase in both the androgen-depleted and high-
density models. Based on this observation, we further
examined expression levels of cyclin D family proteins,
which are important factors in the transition through G1
phase. As shown in Figure 3B, cyclin D1 was down-
regulated in response to high density and androgen deple-
tion in LNCaP cells but not in LAPC-4 cells. In contrast,
cyclin D3 was down-regulated in both cell lines in both
models of NED promotion. We were unable to detect cyc-
lin D2 in LNCaP or LAPC-4 cells (data not shown). We
also analyzed expression of the cyclin-dependent kinase
inhibitors p27Kip1 and p21Cip1. As shown in Figure 3B,
p27Kip1 levels increased in response to high cell density or
androgen depletion whereas p21Cip1 levels decreased in
both models of NED promotion (data not shown). In both
models, the cell cycle arrest observed in the G0/G1 phase
correlated with decreased expression of phosphorylated
retinoblastoma protein (Rb) and decreased total level of
Rb protein (Figure 3B). The Rb protein can be phos-
phorylated on Ser 807/811 by different cyclin dependent
kinases (Cdk) including Cdk4 and Cdk2 [32,33]. As Cdk2
is an important regulator of G1/S transition, we next ex-
amined the activity and expression of Cdk2 in our ex-
perimental models. We detected phosphorylation of
Cdk2 at Thr160, which is crucial for the activation of
Cdk2, and showed that the levels of total and phosphory-
lated Cdk2 decreased in response to androgen depletion
and high cell density (Figure 3B).
Taken together, these results showed that androgen
depletion and high cell density modulate cell cycle ma-
chinery and induce cell cycle arrest in a similar fashion.
To check if the correlation between decreased prolifera-
tion and promotion of NED is also observed in vivo in
human cancer tissue, we examined the expression of NED
markers γ-enolase and chromogranin A and the prolifera-
tion marker Ki-67 by immunohistochemical examination
of formalin-fixed paraffin-embedded tissue samples from
18 patients with advanced prostate adenocarcinoma
(patients information Additional file 4: Table S3; subset of
patients with lymph node metastases was selected in order
to obtain a higher percentage of NED for evaluation).
There was a slight trend towards an inverse correlation
between Ki-67 score and γ-enolase expression (p = 0.146),
suggesting that tumors with slower proliferation (Ki-67
low) have higher expression of the NED marker γ-enolase
(Additional file 5: Figure S4).
Deregulation of cell cycle by inhibition of Cdk1 and/or
Cdk2 activity leads to NED promotion
Next, we focused on elucidating the mechanism under-
lying the promotion of NED by high cell density. Given
that both androgen depletion and high cell density evokes
cell cycle arrest, we hypothesized that modulation of thecell cycle machinery is an important event in promoting
NED in prostate cancer cells.
First, we addressed the role of cyclin D1 and D3 in the
promotion of NED. Using RNA interference approach, we
down-regulated the expression of cyclin D1, cyclin D3, or
both, in LNCaP and LAPC-4 cells. A decrease in cyclin
D1 and/or D3 protein levels led to significant modulation
of the cell cycle; however, modulation of cell cycle pro-
gression by cyclin D1 and D3 down-regulation was not
sufficient for NED promotion in AR-positive LNCaP and
LAPC-4 cells (Additional file 6: Figure S5).
Because androgen depletion and high cell density both
decreased the expression and activity of Cdk2 and
increased expression of the Cdk2 inhibitor p27Kip1, we
next focused on the role of these molecules in deregula-
tion of the cell cycle and the subsequent promotion of
NED. Using a p27Kip1 RNAi approach we were unable to
detect any changes in the cell cycle in LAPC-4 cells,
although p27Kip1 was effectively down-regulated in these
cells (data not shown). We therefore focused on Cdk2 and
used a reversible ATP-competitive inhibitor, CVT-313, to
inhibit Cdk2 activity. Efficient inhibition of Cdk2 activity
by CVT-313 was demonstrated by de-phosphorylation of
Ser 807/811 in the Rb protein, a downstream target of
Cdk2 (Figure 4A). This was accompanied by deregulation
of the cell cycle, as reflected by a decrease in the percent-
age of cells in S-phase and a significant arrest of cells in
G2/M phase (Figure 4B). Importantly, this down-regu
lation of Cdk2 activity and cell arrest in the G2/M phase
was followed by up-regulation of the NED marker γ-
enolase at both protein and mRNA levels (Figures 4C, D).
Next, we performed experiments using specific siRNA
to down-regulate expression of Cdk2. RNAi led to signifi-
cant down-regulation of Cdk2 protein level but had no
significant effects on the cell cycle in LNCaP and LAPC-4
cells (data not shown). Because CVT-313 inhibitor was
shown to also inhibit Cdk1 activity in complex with cyclin
B (IC50 4.2 μM) [34], we next performed experiments
using specific siRNAs against Cdk1 or Cdk2 to elucidate
whether the effects observed with CVT-313 treatment
were caused by decreased activity of both Cdk1 and Cdk2.
Co-transfection of LAPC-4 cells with Cdk1- and Cdk2-
specific siRNAs led to decreased levels of both proteins to
a different degree (Figure 4E). This was associated with
modulation of the cell cycle, as documented by the
increased percentage of cells in G2/M phase after trans-
fection with the siRNAs (Figure 4F). Next, we investigated
whether this cell cycle deregulation affected NED promo-
tion. Detection of mRNA levels of selected NED markers
showed a trend of increased expression of TUBB3 (118%)
and CHGA (117%) (Figure 4G). To further investigate the
role of Cdk1 inhibition in promoting NED we inhibited
Cdk1 using two selective inhibitors, CGP 74514A and
RO-3306 (Figure 4 H-J). Treatment with these inhibitors
Figure 4 (See legend on next page.)
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Figure 4 Deregulation of the cell cycle by inhibition of Cdk1 and/or Cdk2 boosts expression of NED markers in AR-positive prostate
cancer cell lines. A-D, LAPC-4 cells were treated with an inhibitor of Cdk2 activity, CVT-313 (10 μM, 48 h). A, Western blot analysis of Rb protein.
B, Analysis of cell cycle distribution. The data represent means ± SD (n=4). C, Western blot analysis of expression of γ-enolase and tubulin β-III. D,
qRT-PCR analysis of TUBB3, CHGA, and ENO2 mRNA level. The data represent means ± SD (n=4). “*” denotes statistical significance compared with
control. E-G, LAPC-4 cells were transfected with control siRNA or with a combination of Cdk1- and Cdk2 siRNAs for 48 hours. E, Western blot analysis
of Cdk1 and Cdk2 48 hours after transfection. F, Analysis of cell cycle distribution in response to Cdk1 and Cdk2 down-regulation. The data represent
means ± SD (n=3). G, qRT-PCR analysis of changes in mRNA levels of TUBB3 and CHGA in response to Cdk1 and Cdk2 down-regulation. The data
represent means ± SD (n=4). “*”denotes statistical significance compared with control siRNA. H-J, LNCaP and LAPC-4 cells were treated with DMSO or
the indicated Cdk1 inhibitors for 48 hours (LNCaP: 2 μM CGP, 7.5 μM RO; LAPC-4: 3.5 μM CGP, 7.5 μM RO). H, Analysis of cell cycle distribution in LNCaP
and LAPC-4 cells treated with the indicated Cdk1 inhibitors. The data are presented as means ± SD of one out of two independent experiments
performed in duplicate. I, Western blot analysis of γ-enolase and tubulin β-III in response to Cdk1 inhibitors. J, qRT-PCR analysis of TUBB3 and ENO2 in
response to Cdk1 inhibitors. The data are presented as means ± SD of one out of two experiments performed in duplicate. CGP, CGP 74514A; RO, RO-3306.
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cycle in both LNCaP and LAPC-4 cell lines, particularly
after treatment with RO-3306 (Figure 4H). This cell cycle
deregulation was associated with a trend of increased
expression of the NED markers γ-enolase and tubulin β-
III at the protein and/or mRNA level (Figure 4I,J) in
LNCaP cells, but not in LAPC-4.
In summary, these results showed that deregulation of
the cell cycle by inhibition of the activity of the upstream
signaling molecules Cdk1 and Cdk2 is at least partly
involved in NED modulation in AR-positive prostate
cancer cell lines LNCaP and LAPC-4.
cAMP signaling is involved in NED promotion in response
to high cell density
Finally, we aimed to identify the signaling pathway
responsible for NED promotion in response to high cell
density. It has previously been shown that high cell
density is associated with changes in the extracellular to
intracellular distribution of cAMP, which acts as a
second messenger in G-protein coupled pathways [19].
Moreover, it is known that cAMP signaling is involved
in the promotion of NED [11,35]. Therefore, we investi-
gated the involvement of cAMP signaling in NED
promoted by high cell density. To assess the status of
this pathway, we examined changes in phosphorylation
(activation) of the cAMP-dependent protein kinase A
regulatory subunit 2 (PKA RII) and cAMP responsive
element-binding (CREB) protein in response to high cell
density. As shown in Figure 5A, levels of both p-CREB
(Ser133) and p-PKA RII (Ser96) increased in response to
high cell density in LNCaP and LAPC-4 cells. To
confirm that PKA, the key downstream molecule in
cAMP signaling, is activated by high cell density, we
measured the global pattern of phosphorylation of PKA
substrates by western blot analysis. The activity of PKA
was increased in both LNCaP and LAPC-4 cells after
prolonged periods of cultivation at high cell density, as
documented by an increase in overall phosphorylation of
PKA substrates (Figure 5B). Next, we focused on func-
tional validation of the involvement of cAMP signalingin NED promoted by high cell density using an irrevers-
ible inhibitor of adenylate cyclase, MDL-12330A. Cells
were cultivated for 8 days in FBS with MDL-12300A or
vehicle. Long-term treatment of LAPC-4 cells with
MDL-12330A led to inhibition of cAMP/PKA signaling,
as confirmed by inhibition of the global phosphorylation
pattern of PKA substrates (Figure 5C). This inhibition of
cAMP signaling led to a significant inhibition of NED, as
confirmed by decreased protein and mRNA levels of the
NED marker, γ-enolase (Figures 5D and E). These results
confirmed our hypothesis that cAMP signaling is in-
volved in NED evoked by high cell density in AR-
positive prostate cancer cells.
Discussion
To our knowledge, this is the first demonstration that
the plasticity of prostate cancer cells enables promotion
of NED by modulation of the cell cycle in conditions of
high cell density. It has been shown that NED can be
induced predominantly by androgen depletion [6,7], but
also by a wide variety of other stimuli, including IL-6 [8],
Wnt(s) [9], EGF [10], or cAMP signaling [11,12,27]. An-
drogen deprivation therapy (ADT) represents a standard
treatment for advanced prostate cancer [36]. The action of
androgens is predominantly mediated through AR and its
co-activators, which have been shown to be critical regula-
tors of the G1 to S transition in prostate cancer cells
[16,17]. The important role of cyclin D1 and cyclin D3 in
this process was demonstrated by Xu et al. [37]. However,
the link between ADT-induced NED and mechanisms of
cell cycle regulation remains unclear. Here, we showed
that androgen depletion and high cell density both led to
the promotion of NED and modulation of the cell cycle
machinery in a very similar manner, although inhibition of
AR activity was confirmed only in androgen-depleted con-
ditions and not in the high cell density condition. We
demonstrated that Cdk1 and/or Cdk2 inhibition, but not
cyclin D1 or D3 down-regulation, is sufficient for NED
promotion in the presence of androgens. More import-
antly, we identified a key role of the cAMP/PKA signaling
pathway in NED promoted by high cell density. Our study
Figure 5 Involvement of the cAMP signaling pathway in NED promoted by high cell density. Western blot analysis of changes in
expression of selected members of the cAMP signaling pathway in response to high cell density. A, Phosphorylation of PKA RII (Ser 96),
phosphorylation of CREB (Ser 133), and total level of CREB were detected in cells cultivated in complete media with androgens (FBS) for 2 to
16 days. B, Analysis of p-(Ser/Thr) PKA substrates in cells cultivated in the presence of androgens for 2 to 16 days. C, Analysis of the p-Ser/Thr PKA
substrate in LAPC-4 cells in response to treatment with the MDL-12330A, an inhibitor of cAMP signaling. Cells were treated with 2 μM MDL-12330A for
8 days. D, Analysis of the expression of the NED marker γ-enolase in response to treatment with MDL-12330A. E, qRT-PCR analysis of mRNA levels of
ENO2 in response to inhibition of cAMP signaling. The data represent means ± SD of three experiments. “*” and “#” denote statistical significance
compared with control cells harvested on day 0 or cells cultivated for 8 days and treated with vehicle, respectively. F, Schematic illustration of the
proposed mechanism for the promotion of NED by high cell density.
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density could modulate the plasticity of prostate cancer
cells and influence disease progression.
In our previous study, we demonstrated that both andro-
gen depletion and high cell density cultivation led to
increased expression of cytokeratins, general markers of
epithelial differentiation [38]. Because androgen deprivation
is a well-known promoter of NED [39], we compared the
expression of NED markers between prostate cancer cells
cultured at high density and cells cultured in the absence of
androgens. Surprisingly, androgen depletion and high cell
density both promoted increase in expression of several
NED markers (γ-enolase, tubulin β-III, and aromatic L-
amino acid decarboxylase) in prostate cancer cells. The
effect of high density on NED promotion is androgen-
independent, since similar regulation of NED markers was
observed in C4-2 cells, an androgen-independent sub-line
of LNCaP. Moreover, a similar high density-induced
increase in the level of NED markers was detected using
the AR-negative prostate cell line BPH-1 and its tumori-
genic derivative CAFTD03, as well as the cancer cell lines
DU-145 and PC3. Furthermore, re-introduction of AR into
AR-negative PC3 cells did not have any effect on high cell
density-induced NED. This phenotype was also confirmed
in a 3D culture system in all above mentioned cell lines.
Moreover, we observed a slight trend towards the correl-
ation between decreased proliferation and NED promotion
in a small cohort of patients with advanced prostate cancer.
This is in contrast to previously published data showing
that a high Ki-67 labeling index is weakly associated with
high chromogranin A expression (Spearman’s correlation
0.164) [40]. However, the authors of that study showed no
correlation between Ki-67 labeling index and expression of
AR or NeuroD1, another neuroendocrine marker. NeuroD1
was previously shown to be expressed in aggressive prostate
cancer cell lines and prostate cancer samples, although co-
expression with chromogranin A was found only rarely
[41]. Bubendorf et al. [42] did not found significant associ-
ation between Ki-67 and neuroendocrine differentiation
while Grobholz et al. [43] observed higher proliferation
index (assessed by Ki-67) in tumors with large clusters of
NE differentiation in comparison to negative tumors or
with solitary NE cells. With respect to our observations
(both in-vitro and in our small patient cohort) and varying
results in the literature, we may state that the neuroendo-
crine transdifferentiation may be present in tumors with
slower proliferation in some patients.
Because the correlation of NED with cell cycle arrest
had been described in several experimental models
[35,44], we next focused on modulation of the cell cycle
machinery. We showed that the induction of cell cycle
arrest by androgen depletion is associated with down-
regulation of cyclin D1 protein in LNCaP cells but not
in LAPC-4 cells, and with down-regulation of cyclin D3in both cell lines. Similar effects were observed when
NED was promoted by high cell density. These results
are in accordance with previously published data showing
that androgen-induced proliferation of prostate cancer
cells is accompanied by increased levels of D-type cyclins
[37] and, conversely, androgen deprivation causes down-
regulation of protein levels of cyclin D1 and cyclin D3 in
LNCaP cells [16,37]. RNAi-mediated down-regulation of
cyclin D1 in LNCaP cells and cyclin D3 in LAPC-4 cells
led to modulation of the cell cycle and an increased per-
centage of cells in the G0/G1 phase; however, this was not
associated with the promotion of NED. Thus, we conclude
that although the down-regulation of D-type cyclins leads
to cell cycle arrest in the G0/G1 phase, it is not sufficient
for promoting NED in AR-positive prostate cancer cells.
Next, we focused on the role of the more general cell
cycle regulator Cdk2. Both the activity and expression of
Cdk2 were down-regulated during NED promotion by
androgen depletion and high cell density, and this down-
regulation correlated with up-regulation of the Cdk inhibi-
tor p27Kip1 in both of our models. It was previously shown
that Cdk2 expression and activity together with Rb protein
phosphorylation, are regulated by androgens [16,45]. Gen-
erally, inhibition of Cdk activity causes cell cycle arrest
and inhibits proliferation of prostate cancer cells. Our
results showed that inhibition of Cdk2 causes cell cycle
attenuation, in particular accumulation in the G2/M phase
in LAPC-4 cells; this arrest is associated with significant
promotion of NED. These results, which indicate a func-
tional role of the inhibition of Cdk2 activity in the regula-
tion of NED, are supported by the findings of other
investigators. For example, it has been reported that
silibinin-induced NED in LNCaP cells is also associated
with cell cycle arrest and decreased Cdk2 levels [46]. We
did not observe a significant change in the expression of
NED markers when Cdk2 expression was reduced using a
siRNA-mediated approach (data not shown). However,
transfection of Cdk2 siRNA in combination with Cdk1
siRNA resulted in a slight trend towards NED promotion.
This observation is in agreement with results obtained
using CVT-313 inhibitor, which at the applied dose prefer-
entially inhibits Cdk2, but might also partially inhibit
Cdk1 [34]. To reveal the role of Cdk1 in NED promotion
we used selective inhibitors. Treatment with subtoxic con-
centrations of the Cdk1-specific inhibitor CGP 74514 only
slightly modulated the cell cycle, whereas RO-3306 caused
accumulation of cells in G2/M phase, in accordance with
previously published data [47]. This was accompanied by
increased expression of NED markers at the protein and
mRNA level in LNCaP cells but not in LAPC-4 cells,
which only showed up-regulation of γ-enolase expression
at the protein level. Further studies of the mechanisms by
which Cdk1 and Cdk2 are involved in the plasticity of
prostate cancer cells are necessary based on the fact that
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and activity were not uniformly reflected in terms of NED
promotion. Since experiments for elucidating the involve-
ment of Cdk1 and Cdk2 in promoting NED were
performed only in AR-positive prostate cancer cell lines,
investigating the AR-negative cell lines might shed more
light in proposed role of Cdk1 and Cdk2 deregulation in
promoting NED. Our observations suggest that the associ-
ation between NED and the cell cycle, and the role of par-
ticular regulators of cell cycle machinery is more complex
and also cell type-dependent. The clinical potential of
pharmacological inhibition of Cdk activity in cancer ther-
apy has been demonstrated in several studies (for review
see [48]). However, based on our observations, it is im-
portant to consider the possible effects of Cdk1 and Cdk2
inhibition in NED promotion in prostate cancer cells.
It has previously been shown that NED can be induced
by physiological and pharmacological agents that elevate
intracellular cAMP levels [27]. Treatment of prostate can-
cer cells with cAMP leads to changes in the expression of
Hox genes located at the HOXD locus [13] including the
Neuro D1 transcription factor, which is expressed in ma-
lignant NE cells [41]. Moreover, other downstream targets
of cAMP, PKA [11] and CREB [14], are directly involved
in NED. Furthermore, promotion of NED by cAMP-
inducing agents is a reversible process. Interestingly, it has
been shown that the cAMP level can be modulated by cell
density [19]. Based on these facts, we hypothesized that
the promotion of NED by high cell density can be medi-
ated by the activation of cAMP signaling. Our results
demonstrated that cAMP signaling is indeed activated in
response to high cell density, as demonstrated by in-
creased levels of downstream target molecules of cAMP,
such as phosphorylated PKA regulatory subunit II and
phosphorylated CREB. Interestingly, cAMP inhibits prolif-
eration of breast cancer cells via increased expression of
p27Kip1 and decreased activity of Cdk2 [49]. These obser-
vations are indirectly in accordance with our observation,
since in response to high cell density we observed in-
creased activation of cAMP-mediated signaling, increased
p27Kip1, and decreased Cdk2 expression. Moreover, it was
shown that cAMP inhibits Cdk2 activity and Rb phos-
phorylation in adipose stem cells [50]. More importantly,
the functional involvement of cAMP was confirmed by
the demonstration that treatment of prostate cancer cells
with MDL-12330A, a potent inhibitor of adenylate cy-
clase, abolished the promotion of NED by high cell dens-
ity. In summary, these experiment support our hypothesis
that activation of cAMP signaling mediates NED promo-
tion by high cell density in AR-positive prostate cancer
cell lines (Figure 5F). Based on our results we conclude
that modulation of the cell cycle by high cell density can
promote reversible NED in prostate epithelial cancer cells.
Our study also suggests that prostate cancer tissueremodeling, in association with disease progression or
therapy, might contribute to tumor progression by modu-
lating the plasticity of cancer cells and by promoting NED.Conclusions
We have demonstrated a new relationship between high
cell density, cell cycle attenuation, and promotion of
NED and suggest high cell density as a trigger for cAMP
signaling that can mediate reversible NED in prostate
cancer cells.Materials and Methods
Cell culture and treatment
LNCaP cells (DSMZ) [51] (androgen-sensitive cell line
carrying mutation in the gene encoding AR [52]), and
LAPC-4 cells (androgen-dependent cell line carrying
WT gene encoding AR [53]) were cultivated as described
previously [38]. Culture conditions for the androgen-
independent subline C4-2 [54] were similar to those for
the parental LNCaP cell line. Under experimental condi-
tions (high-density NED promotion, siRNA transfection,
treatment with inhibitors), LNCaP cells were cultivated
with 5% FBS or 5% dextran/charcoal-stripped FBS (CS, for
androgen depletion), and LAPC-4 cells were cultivated
with 10% FBS and 1 nM R1881, or with 10% CS. BPH-1
cells [55] and the BPH-1 tumorigenic clone CAFTD03
[56] were cultivated as described previously [57]. PC3
(ATCC) and PC3 cells stably expressing AR [30] were
cultivated in F12 with 10% FBS and penicillin and strepto-
mycin. DU-145 cells (ATCC) were cultivated in RPMI
1640 with 10% FBS and penicillin and streptomycin.
AmpFLSTR® Identifiler® PCR Amplification Kit (Life
Technologies) was used to verify the origin of cell lines.
To evoke NED, LNCaP and LAPC-4 cells were culti-
vated as follows: cells were seeded at a density of 20,000/
cm2 in the appropriate complete medium with FBS
(day -1). After 24 hours, the medium was exchanged for
medium with FBS or CS (day 0). Cells were continuously
cultivated for 2 to 16 days without splitting, but with
exchange of the medium for fresh medium twice a week.
Cells were collected for further analysis on days 2, 4, 8,
and 16 after the change of medium on day 0.
For cultivation in 3D conditions, we used Alvetex® poly-
styrene scaffold inserts in 6-well plates (AVP004), 12-well
plates (AVP002), or 24-well plates (AVP006) containing
200 μm thick Alvetex polystyrene scaffold (Reinnervate).
Cells were seeded at a density of 0.5 × 106, 1.0 × 106, and
1.5 × 106 cells per insert and cultivated for 72 to 96 hours
with regular media exchanges. Cells that were seeded on
standard Petri dishes in standard media and at standard
seeding densities and cultivated for either 1 day or 4 days
were used as a 2D control. Experiments in 3D were per-
formed with two independent repetitions.
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ATP-competitive Cdk2 inhibitor III [CVT-313, 2 (bis-
(Hydroxyethyl) amino)-6-(4-methoxybenzylamino)-9-iso-
propyl-purine)] (#238803 Merck). For inhibition of Cdk1
activity we used the Cdk1 inhibitor CGP 74514A [N-(cis-2-
Aminocyclohexyl) -N-(3-chlorophenyl)-9-ethyl-9H-purine-
2,6-diamine, #217696, Calbiochem] and ATP-competitive
Cdk1 Inhibitor IV RO-3306 [(5Z)-2-((Thiophen-2-yl)
methylamino)-5-((quinolin-6-yl) methylene) thiazol-4(5H)-
one, #217699, Calbiochem], both dissolved in DMSO. For
inhibition of cAMP signaling we used an adenylate cyclase-
specific inhibitor MDL-12330A hydrochloride [N- (cis-2-
phenyl-cyclopentyl) azacyclotridecan-2-imine-hydrochlor-
ide, M-182, Sigma-Aldrich]. For all treatments, LNCaP and
LAPC-4 cells were seeded at a density of 20,000 or 30,000
cells/cm2 in appropriate media (IMDM+ 10% FBS + 1 nM
R1881 + antibiotics for LAPC-4, RPMI + 5% FBS + antibi-
otics for LNCaP cells). After 48 hours, cells were treated
with the indicated concentrations of selected inhibitors and
control cells were treated with the equivalent concentration
of dMSO (not exceeding 0.1%). Cells were collected for fur-
ther analysis 48 hours after treatment. All experiments were
performed at least twice with technical duplicates.
Cell cycle analysis
Cells were fixed, stained, and analyzed by flow cytome-
try using FACSCalibur™ or BD FACSVerse (Becton
Dickinson) as described previously [33]. At least two
independent repetitions were performed for each
experiment.
Cell transfection and RNA interference
LNCaP and LAPC-4 cells were transfected with small in-
hibitory RNA (siRNA) duplexes (Santa Cruz Biotechnology)
directed against non-targeting control (sc-37007), Cdk1
siRNA (sc-29252), and Cdk2 siRNA (sc-156139) using the
Neon® Transfection System (Life Technologies). Transfec-
tion was performed in a 10-μl tip according to the manufac-
turer’s recommendations. Cells were harvested 48 hours
after transfection for further analysis. Experiments were
performed in three independent repetitions.
RNA isolation and real-time reverse transcription
polymerase chain reaction (qRT-PCR)
Total RNA was isolated using High Pure RNA Isolation
Kit (Roche). PCR was performed using the One Step
SYBR® PrimeScript™ RT-PCR Kit II (Perfect Real Time)
according to the manufacturer’s recommendations on a
RotorGene 6000 (Corbett Research) [33]. The sequences
of the primers used are listed in Additional file 7: Table
S1-A. Changes in gene expression were calculated using
the comparative threshold cycle method, with POLR2A as
a normalizing gene [58]. Data from at least three experi-
ments were normalized for each gene using the mean CTvalue for the control sample (2 days of incubation with
FBS, control siRNA, vehicle-treated cells, or cells har-
vested at day 0). Alternatively, two-step qRT-PCR was
performed. Up to 1 μg of isolated RNA was reverse tran-
scribed to cDNA with the High Capacity RNA-to-cDNA
Kit (Applied Biosystems). qRT-PCR was performed on a
Light Cycler 480 (Roche) using the Light Cycler 480 Master
Mix in combination with Human Universal Probe Library
(Roche). Primer and probe combinations used in assays are
listed in Additional file 7: Table S1B. Results for genes
of interest were normalized to the housekeeping gene
POLR2a assessed using Light Cycler 480 software and
are presented as 2ΔΔCT . experiments were performed
in at least two independent repetitions or in technical
duplicates.
Electrophoresis and western blotting
Collected cell pellets were lysed and the protein extracts
were separated and blotted as described previously [33].
The primary and secondary antibodies used are listed
in Additional file 8: Table S2. Detection of α-tubulin
and β-actin served as a control of equal loading. All
western blots are presented as typical results of at
least two independent repetitions. Densitometry ana-
lyses were performed using ImageJ software (NIH).
Values given below a particular band represent nor-
malized results of densitometry analysis of the given
image (integrated density for the particular band was
assessed and all values were normalized to the control
of equal loading).
Immunofluorescence microscopy
Cells were cultivated, fixed, permeabilized, and stained
as described previously [38]. The primary and secondary
antibodies used are listed in Additional file 8: Table S2.
Fluorescence images of the cells were obtained using a
confocal microscope (TSC SP5X, Leica Microsystems).
Statistical analysis
Statistical analysis was performed using STATISTICA for
Windows software (StatSoft). When the data variance was
homogenous, one-way analysis of variance followed by the
Fisher or Tukey range test was used. If the data variance
was non-homogenous, the Mann-Whitney U-test was per
formed.
Supplementary Material and Methods can be found in
Additional file 9.
Additional files
Additional file 1: Figure S1. A, Induction of neuroendocrine
transdifferentiation by high cell density, but not by androgen depletion,
is a reversible process. Cells were cultivated for 16 days to induce NED as
described in Material and Methods section. After 16 days the cells were
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media. Cells grown in FBS were re-seeded into media with FBS; cells grown
in CS were re-seeded into either CS or FBS. Cells were further cultivated
for 2, 4, and 8 days (16+2, 16+4, and 16+8, respectively) without splitting
and appropriate medium was exchanged with fresh one twice a
week. Expression of the NED marker γ-enolase in response to re-seeding
was assessed using western blot analysis. A typical result of three independent
repetitions is presented. B-D, NED is promoted by high density also in
AR-negative prostate epithelial cell lines. B, PC-3, PC3-AR, and DU-145
cells were cultivated as described in Supplementary Material and
Methods. Expression of NED markers γ-enolase and tubulin β-III was
assessed by western blot analysis. C, Western blot analysis of AR expression
to confirm its presence in PC3-AR cells; LNCaP cells served as a positive
control. Results from one repetition out of two performed in technical
duplicate are presented. D, qRT-PCR analysis of the NED marker γ-enolase
(ENO2) and tubulin β-III (TUBB3) in PC3, PC3-AR, and DU-145 cells cultivated
as described. Results from two repetitions performed in technical duplicate
are presented (n=4). E, qRT-PCR analysis of DcR2 gene (TNFRSF10D) in
PC3-AR cells cultivated as described in Additional file 9. Results from
two repetitions performed in technical duplicate are presented (n=4).
Additional file 2: Figure S2. Cultivation of prostate cancer cell lines in
3D conditions using Alvetex scaffold. A, LNCaP and LAPC-4 cells were
cultivated in 3D conditions using Alvetex® scaffold at the indicated seeding
densities per insert in complete media. After 72 hours, live cells were
visualized by staining with 0.5% neutral red solution (N6634, Sigma-Aldrich)
according to the manufacturer’s protocol. Increased intensity of staining
indicates increased cell density. B, Immunofluorescence detection of tubulin
β-III expression in LNCaP and LAPC-4 cells after 3 days of cultivation on
Alvetex® inserts. Staining was performed according to the manufacturer’s
protocol. Specifications of the antibodies used are provided in Table S2. C,
qRT-PCR analysis of DcR2 gene (TNFRSF10D) in PC3-AR cells cultivated in 3D
conditions on Alvetex scaffold as described in Additional file 9. The triangle
represents increasing seeding density in 3D conditions on Alvetex (0.5×106,
1.0×106, and 1.5×106, respectively). Results from two
independent repetitions are presented (n=2).
Additional file 3: Figure S3. Assessment of AR activity at a single cell
level after high-density cultivation and prolonged androgen ablation. A,
Activity of AR in response to androgen depletion (12d CS) and at high
density (12d FBS) assessed by detection of KLK3 mRNA using a mRNA
FISH technique and quantified (B) as described in Additional file 9. n,
number of identified nuclei C, Flow cytometric analysis of prostate mem-
brane specific antigen (PSMA) in LNCaP and LAPC-4 cells in response to an-
drogen depletion (8d CS) or high density (8d FBS). Staining was
performed as described in Additional file 9. Representative results from one
repetition out of two performed in replicate are presented. d, days.
Additional file 4: Table S3. Characteristics of human prostate tumor
samples. Subsets of patients with advanced CaP with lymph node
metastases were selected to obtain a sufficient percentage of NED for
statistical evaluation. dg, diagnosis; GS, Gleason score; pT, pathologic T
stage; pN, positivity of lymph nodes; %, percentage of positive staining.
Additional file 5: Figure S4. Immunohistochemical staining of
formalin-fixed paraffin-embedded patient samples. A, Patients 2 and 9
display low Ki-67 expression (less than 30% nuclear positivity) and
multiple chromogranin A- and γ-enolase-positive NE and/or NE-like cells.
Patients 13 and 15 display high Ki-67 expression (more than 30% nuclear
positivity) and single chromogranin A and γ-enolase-positive NE and/or
NE-like cells (magnification 40×). B, Quantification of γ-enolase and
chromogranin A expression in patient tumor samples. In total, 10 patients
with low Ki-67 expression and 8 patients with high Ki-67 expression were
examined. Information on the patients is provided in Table S3.
Additional file 6: Figure S5. Modulation of the cell cycle by
down-regulation of cyclin D1 and/or cyclin D3 does not lead to
induction of NED in LNCaP and LAPC-4 cells. A, Western blot analysis
of the efficiency of cyclin D1 and cyclin D3 down-regulation in LNCaP and
LAPC-4 cells following transfection with control siRNA A or specific siRNA
(20 or 40 nM). Experiments were performed as described in Supplementary
Materials and Methods. B, Analysis of changes in cell cycle distribution in
response to cyclin D1 and/or cyclin D3 down-regulation in LNCaP and
LAPC-4 cells. Data represent means ± SD of three independent experiments.C, Western blot analysis of changes in protein levels of NED markers in
response to cyclin D1 and/or cyclin D3 siRNA. It should be noted that other
samples irrelevant to this study were analyzed on the same membranes.
These samples were omitted from the pictures presented and the western
blots presented here are therefore cropped. D, qRT-PCR analysis of changes
in mRNA level of the NED marker γ-enolase (ENO2) in response to cyclin D1
and/or cyclin D3 siRNA. Data represent means ± SD of two independent
experiments performed in duplicate (n=4). “*” and “#” denote statistical
significance (P<0.05) compared with cells transfected with 20 nM or 40 nM
control siRNA A, respectively.
Additional file 7: Table S1. Sequences of primers used in quantitative
RT-PCR.
Additional file 8: Table S2. Specification of antibodies used for
western blot analysis, immunofluorescence and flow cytometry.
Additional file 9: Supplementary Material and Methods.
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